COYA · Coya Therapeutics, Inc.

Coya Therapeutics, Inc. (COYA) reported Q1 2026 results reflecting continued investment in its immunology-focused pipeline, particularly COYA 302 for ALS, while navigating revenue timing and cost dynamics. Revenue of $251.1K represented a 2.6% YoY decline from $257.9K. This decrease was primarily due to lower external preclinical and clinical product candidate expenses, reflecting the timing of activities undertaken in early 2025 to support IND applications for COYA 302 in ALS, as noted in Management's Discussion and Analysis.

Cash flow from operations reflected heightened activity, with net cash used rising to $6.2M from $2.8M YoY. This acceleration aligns with the Company's primary use of cash to fund operating expenses, especially research and development. Since inception, Coya has incurred operating losses through March 31, 2026, and currently maintains no credit facility or committed capital sources. Management emphasizes the need to raise substantial additional capital to sustain operations and pursue growth, with future requirements depending on multiple factors including those outlined in Risk Factors.

The Company operates without discrete segment reporting, as operating segments are evaluated holistically by the chief operating decision-maker for resource allocation and performance assessment. General and administrative expenses are expected to rise to support expanded R&D, potential commercialization, and public company costs. Fair value measurements for cash equivalents, accounts payable, and accrued expenses approximate carrying amounts due to their short-term nature. Revenue recognition for R&D services employs an expected cost-plus margin approach.

These results underscore Coya's focus on advancing its therapeutic candidates amid clinical development timing, with operating improvements providing some offset to increased cash needs. Investors should monitor capital raise progress and pipeline milestones, given liquidity risks and dependence on external funding.